5.
Pereira D, Guevara C, Jin L, Mbong N, Verlinsky A, Hsu S
. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Mol Cancer Ther. 2015; 14(7):1650-60.
PMC: 4557793.
DOI: 10.1158/1535-7163.MCT-15-0067.
View
6.
Lichtman M
. Interrupting the inhibiton of normal hematopoiesis in myelogenous leukemia: a hypothetical approach to therapy. Stem Cells. 2000; 18(5):304-6.
DOI: 10.1634/stemcells.18-5-304.
View
7.
Aubrey B, Kelly G, Kueh A, Brennan M, OConnor L, Milla L
. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015; 10(8):1422-32.
DOI: 10.1016/j.celrep.2015.02.002.
View
8.
Ley T, Miller C, Ding L, Raphael B, Mungall A, Robertson A
. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22):2059-74.
PMC: 3767041.
DOI: 10.1056/NEJMoa1301689.
View
9.
Stathis A, Flinn I, Madan S, Maddocks K, Freedman A, Weitman S
. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Invest New Drugs. 2018; 36(5):869-876.
PMC: 6153548.
DOI: 10.1007/s10637-018-0570-4.
View
10.
Caulier B, Joaquina S, Gelebart P, Dowling T, Kaveh F, Thomas M
. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. Cell Rep Med. 2024; 5(6):101572.
PMC: 11228397.
DOI: 10.1016/j.xcrm.2024.101572.
View
11.
Hemler M
. Specific tetraspanin functions. J Cell Biol. 2002; 155(7):1103-7.
PMC: 2199333.
DOI: 10.1083/jcb.200108061.
View
12.
McCluskey A, Daniel J, Hadzic G, Chau N, Clayton E, Mariana A
. Building a better dynasore: the dyngo compounds potently inhibit dynamin and endocytosis. Traffic. 2013; 14(12):1272-89.
PMC: 4138991.
DOI: 10.1111/tra.12119.
View
13.
Medeiros B, Satram-Hoang S, Hurst D, Hoang K, Momin F, Reyes C
. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015; 94(7):1127-38.
PMC: 4432101.
DOI: 10.1007/s00277-015-2351-x.
View
14.
Remillard S, REBHUN L, Howie G, Kupchan S
. Antimitotic activity of the potent tumor inhibitor maytansine. Science. 1975; 189(4207):1002-5.
DOI: 10.1126/science.1241159.
View
15.
Jager P, Geyh S, Twarock S, Cadeddu R, Rabes P, Koch A
. Acute myeloid leukemia-induced functional inhibition of healthy CD34+ hematopoietic stem and progenitor cells. Stem Cells. 2021; 39(9):1270-1284.
DOI: 10.1002/stem.3387.
View
16.
Eisfeld A, Kohlschmidt J, Mrozek K, Volinia S, Blachly J, Nicolet D
. Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. Cancer Res. 2016; 77(1):207-218.
PMC: 5215102.
DOI: 10.1158/0008-5472.CAN-16-1386.
View
17.
Lapalombella R, Yeh Y, Wang L, Ramanunni A, Rafiq S, Jha S
. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 2012; 21(5):694-708.
PMC: 3360882.
DOI: 10.1016/j.ccr.2012.03.040.
View
18.
Chari R
. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2007; 41(1):98-107.
DOI: 10.1021/ar700108g.
View
19.
Walter R, Appelbaum F, Estey E, Bernstein I
. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012; 119(26):6198-208.
PMC: 3383202.
DOI: 10.1182/blood-2011-11-325050.
View